Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Bhatt

Showing results (441-450 of 578) with videos related to

Pageof 58
Sort By:
The Lancet. Respiratory Medicine|February 3, 2025
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trialsSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Respiratory Medicine|March 2, 2025
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scoresClaus F Vogelmeier, Klaus F Rabe, Surya P Bhatt, et al.
American Journal of Epidemiology|April 15, 2020
A Dyadic Growth Modeling Approach for Examining Associations Between Weight Gain and Lung Function DeclineTalea Cornelius, Joseph E Schwartz, Pallavi Balte, et al.
The Lancet. Respiratory Medicine|July 12, 2025
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trialStephanie A Christenson, Nicola A Hanania, Surya P Bhatt, et al.
Chest|February 2, 2025
Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUSSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Journal of Computer Assisted Tomography|September 17, 2016
Arterial and Venous Pulmonary Vascular Morphology and Their Relationship to Findings in Cardiac Magnetic Resonance Imaging in SmokersFarbod N Rahaghi, J Michael Wells, Carolyn E Come, et al.
Respiratory Medicine|October 31, 2024
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)Surya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
American Journal of Respiratory and Critical Care Medicine|May 20, 2021
Pulmonary Artery Enlargement Is Associated with Exacerbations and Mortality in Ever-Smokers with Preserved Ratio Impaired SpirometryR Chad Wade, J Patrick Simmons, Adel Boueiz, et al.
American Journal of Respiratory and Critical Care Medicine|April 26, 2017
Cardiac Morphometry on Computed Tomography and Exacerbation Reduction with β-Blocker Therapy in Chronic Obstructive Pulmonary DiseaseSurya P Bhatt, Gonzalo Vegas-Sánchez-Ferrero, Farbod N Rahaghi, et al.
Field Crops Research|June 18, 2021
An impact of agronomic practices of sustainable rice-wheat crop intensification on food security, economic adaptability, and environmental mitigation across eastern Indo-Gangetic PlainsJ S Mishra, S P Poonia, Rakesh Kumar, et al.
Pageof 58

Showing results (441-450 of 578) with videos related to

Sort By:
Pageof 58
The Lancet. Respiratory Medicine|February 3, 2025
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trialsSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Respiratory Medicine|March 2, 2025
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scoresClaus F Vogelmeier, Klaus F Rabe, Surya P Bhatt, et al.
American Journal of Epidemiology|April 15, 2020
A Dyadic Growth Modeling Approach for Examining Associations Between Weight Gain and Lung Function DeclineTalea Cornelius, Joseph E Schwartz, Pallavi Balte, et al.
The Lancet. Respiratory Medicine|July 12, 2025
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trialStephanie A Christenson, Nicola A Hanania, Surya P Bhatt, et al.
Chest|February 2, 2025
Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUSSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Journal of Computer Assisted Tomography|September 17, 2016
Arterial and Venous Pulmonary Vascular Morphology and Their Relationship to Findings in Cardiac Magnetic Resonance Imaging in SmokersFarbod N Rahaghi, J Michael Wells, Carolyn E Come, et al.
Respiratory Medicine|October 31, 2024
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)Surya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
American Journal of Respiratory and Critical Care Medicine|May 20, 2021
Pulmonary Artery Enlargement Is Associated with Exacerbations and Mortality in Ever-Smokers with Preserved Ratio Impaired SpirometryR Chad Wade, J Patrick Simmons, Adel Boueiz, et al.
American Journal of Respiratory and Critical Care Medicine|April 26, 2017
Cardiac Morphometry on Computed Tomography and Exacerbation Reduction with β-Blocker Therapy in Chronic Obstructive Pulmonary DiseaseSurya P Bhatt, Gonzalo Vegas-Sánchez-Ferrero, Farbod N Rahaghi, et al.
Field Crops Research|June 18, 2021
An impact of agronomic practices of sustainable rice-wheat crop intensification on food security, economic adaptability, and environmental mitigation across eastern Indo-Gangetic PlainsJ S Mishra, S P Poonia, Rakesh Kumar, et al.
Pageof 58